EGFR and non-small cell lung carcinoma: Erlotinib (TarcevaTM, CP-358774) was approved by the FDA in 2004 as the first-line treatment of metastatic NSCLC with mutated EGFR, such as deletion in exon 19 and L858R substitution [110].